Cold agglutinin disease drug safety study ends early
NCT ID NCT04802057
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study looked at the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare autoimmune condition where the body attacks its own red blood cells. It included 9 adults who had either taken the drug before or were new to it. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2760001
Essen, 45147, Germany
-
Investigational Site Number : 3800001
Milan, Milano, 20122, Italy
-
Investigational Site Number : 5280001
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number : 5780001
Bergen, 5021, Norway
-
Investigational Site Number : 8260001
London, London, City of, NW1 2PG, United Kingdom
Conditions
Explore the condition pages connected to this study.